A Blood Hepatocellular Carcinoma Signature Recognizes Very Small Tumor Nodules with Metastatic Traits (IMAGE)
Caption
The pre-RFA blood HCC signature developed in the present study, which considers the blood levels of DCP (≥40 mAU/mL) and the cfDNA mutation score generated from cfDNA mutations in TP53, CTNNB1 and the TERT promoter, effectively identified small HCC nodules with metastatic traits. The optimal adjuvant therapies for patients at high-risk for early HCC recurrence differ from those for patients at risk for late recurrence. Examination of the pre-RFA HCC blood signature may be used to predict early HCC recurrence post-RFA, potentially informing individualized planning of adjuvant therapy to prevent recurrence of metastatic primary tumors.
Credit
Hui Xie, Kun Chen, Junxiao Wang, Liping Jiang
Usage Restrictions
Credit must be given to the creator. Only noncommercial uses of the work are permitted.
License
CC BY-NC